DieringerTDSchaenmanJMDavisMR.Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules. J Antimicrob Chemother. 2022;77:1417-1423. doi:10.1093/jac/dkac035.
3.
ManeshADevasagayamEBhanuprasadK, et al. Efficacy of crushed delayed-release posaconazole tablets in rhino-orbito-cerebral mucormycosis. Antimicrob Agents Chemother. 2022;66:e0108522. doi:10.1128/aac.01085-22.
4.
StevensRWO’ConnellCHuangAEppsKLIlgesD.Therapeutic drug monitoring following crushed administration of delayed-release posaconazole tablets via enteral feeding tubes. J Antimicrob Chemother. 2023;78:553-555. doi:10.1093/jac/dkac427.
McCrearyEKDavisMRNarayananN, et al. Utility of triazole antifungal therapeutic drug monitoring: insights from the society of infectious diseases pharmacists. Pharmacotherapy. 2023;43(10):1043-1050. doi:10.1002/phar.2850.
7.
PasTVerbertSAppeltansBVan den MooterG.The influence of crushing amorphous solid dispersion dosage forms on the in-vitro dissolution kinetics. Int J Pharm. 2020;5:573. doi:10.1016/j.ijpharm.2019.118884.
8.
RayJCampbellLRudhamSNguyenQMarriottD.Posaconazole plasma concentrations in critically ill patients. Ther Drug Monit. 2011;33(4):387-392. doi:10.1097/FTD.0b013e31821fb197.
9.
SimeFBStuartJButlerJ, et al. Pharmacokinetics of intravenous posaconazole in critically ill patients. Antimicrob Agents Chemother. 2018;62(6):e00242. doi:10.1128/AAC.00242-18.
